Valneva (VALN) secured marketing authorization in the UK for its Ixchiq vaccine for chikungunya, a mosquito-borne viral disease.
The vaccine, manufactured at the company's leading production site in Livingston, Scotland, got the approval from the Medicines and Healthcare products Regulatory Agency,
The single-dose vaccine is for active immunization for the prevention of disease caused by the chikungunya virus in people 18 years of age and older, Valneva said Wednesday in a statement.
The vaccine is approved in the US, Europe and Canada in adults, and Valneva expects to get marketing approval in Brazil in Q1.
Valneva submitted label extension applications in the US, Europe and Canada to possibly extend the use of Ixchiq to adolescents aged 12 to 17 years and plans to submit a label extension application in the UK.
The company's shares rose 14% in recent Wednesday trading.
Price: 6.43, Change: +0.82, Percent Change: +14.69
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.